BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30157797)

  • 1. Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.
    Vekeman F; Weiss L; Aram J; Ionescu-Ittu R; Moosavi S; Xiao Y; Cheng WY; Bhak RH; Tawadrous M; Capparella MR; Montravers P; Duh MS
    BMC Infect Dis; 2018 Aug; 18(1):438. PubMed ID: 30157797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
    Glöckner A
    Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice.
    Chandwani S; Wentworth C; Burke TA; Patterson TF
    Curr Med Res Opin; 2009 Feb; 25(2):385-93. PubMed ID: 19192983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
    Kofla G; Ruhnke M
    Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspofungin versus micafungin in the incidence of hepatotoxicity in patients with normal to moderate liver failure.
    Shibata Y; Hagihara M; Kato H; Kawasumi N; Hirai J; Nishiyama N; Asai N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
    J Infect Chemother; 2017 Jun; 23(6):349-353. PubMed ID: 28431933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients.
    Suh JW; Kim SB; Yoon YK; Sohn JW; Kim MJ; Kim JH
    Mycopathologia; 2020 Aug; 185(4):653-664. PubMed ID: 32705415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests.
    Jung DS; Tverdek FP; Jiang Y; Kontoyiannis DP
    J Antimicrob Chemother; 2015 Nov; 70(11):3100-6. PubMed ID: 26311837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
    Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
    Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of echinocandins in suspected candida peritonitis: A potential risk for resistance.
    Gioia F; Gomez-Lopez A; Alvarez ME; Gomez-García de la Pedrosa E; Martín-Davila P; Cuenca-Estrella M; Moreno S; Fortun J
    Int J Infect Dis; 2020 Dec; 101():24-28. PubMed ID: 32937195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison between micafungin and caspofungin for the empirical treatment of severe intra-abdominal infections in surgical intensive care patients].
    Yan T; Li SL; Wang DX
    Zhonghua Yi Xue Za Zhi; 2016 Aug; 96(29):2301-6. PubMed ID: 27524185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA; Chen A; Buhari M; Chandra J; Mukherjee PK; Baxa D; Golembieski A; Vazquez JA
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.
    Montagna MT; Lovero G; Coretti C; Martinelli D; De Giglio O; Iatta R; Balbino S; Rosato A; Caggiano G
    BMC Microbiol; 2015 May; 15():106. PubMed ID: 25990252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.